---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-029522"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2023-08-21T23:59:59+00:00"
generated_at: "2026-06-11T06:20:05.245933+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivos receives Nasdaq deficiency notice for stockholders' equity below $2.5M

## Summary
- Stockholders' equity as of June 30, 2023 was approx. $2.106M, below Nasdaq's $2.5M minimum.
- Company has until October 2, 2023 to submit a compliance plan to Nasdaq.
- If plan accepted, Nasdaq may grant extension through February 13, 2024.
- Failure to regain compliance could lead to delisting; no immediate impact on listing.

## SEC filing metadata
- accession: 0001493152-23-029522
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2023-08-21T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315223029522/0001493152-23-029522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315223029522/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-029522
- JSON: https://secwatch.observer/filing/0001493152-23-029522.json
- Plain text: https://secwatch.observer/filing/0001493152-23-029522.txt

## Key facts
- Listing & Compliance Notices
  Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: be at least $2,500,000 (the “Minimum Stockholders’ Equity Requirement”). As reported in its Form 10-Q, the Company’s stockholders’ equity as of June 30, 2023 was approximately $2,106,000. The Staff’s notice has no immediate impact on the listing of the Company’s common stock on Nasdaq. In accordance with the Nasdaq Listing Rules, the Company has 45 calendar days,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315223029522/0001493152-23-029522-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.